238 related articles for article (PubMed ID: 34256606)
21. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
22. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.
Biagi E; Capuzzi E; Colmegna F; Mascarini A; Brambilla G; Ornaghi A; Santambrogio J; Clerici M
Adv Ther; 2017 May; 34(5):1036-1048. PubMed ID: 28382557
[TBL] [Abstract][Full Text] [Related]
23. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
[TBL] [Abstract][Full Text] [Related]
24. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
[TBL] [Abstract][Full Text] [Related]
25. Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia.
Kishi T; Sakuma K; Okuya M; Iwata N
J Psychiatr Res; 2021 Jan; 132():144-150. PubMed ID: 33096355
[TBL] [Abstract][Full Text] [Related]
26. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration.
Rosenheck R; Anand ST; Kurtz SG; Hau C; Smedberg D; Pontzer JF; Ferguson RE; Davis CR
Trials; 2023 Feb; 24(1):85. PubMed ID: 36747254
[TBL] [Abstract][Full Text] [Related]
27. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
28. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
29. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
[TBL] [Abstract][Full Text] [Related]
30. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.
Edwards NC; Pesa J; Meletiche DM; Engelhart L; Thompson AK; Sherr J; Dirani R
Curr Med Res Opin; 2008 Dec; 24(12):3341-55. PubMed ID: 18954497
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.
Bitter I; Katona L; Zámbori J; Takács P; Fehér L; Diels J; Bacskai M; Lang Z; Gyáni G; Czobor P
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1383-90. PubMed ID: 23477752
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data.
Efthimiou O; Taipale H; Radua J; Schneider-Thoma J; Pinzón-Espinosa J; Ortuño M; Vinkers CH; Mittendorfer-Rutz E; Cardoner N; Tanskanen A; Fusar-Poli P; Cipriani A; Vieta E; Leucht S; Tiihonen J; Luykx JJ
Lancet Psychiatry; 2024 Feb; 11(2):102-111. PubMed ID: 38215784
[TBL] [Abstract][Full Text] [Related]
33. Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia.
Acosta FJ; Chinea E; Hernández JL; Rodríguez F; García-Bello M; Medina G; Nieves W
Nord J Psychiatry; 2014 Apr; 68(3):180-8. PubMed ID: 23672274
[TBL] [Abstract][Full Text] [Related]
34. Weight gain on antipsychotic medication is associated with sustained use among veterans with schizophrenia.
Monnelly EP; Fonda J; Gagnon DR; Chittamooru S; Lawler EV
J Clin Psychopharmacol; 2015 Feb; 35(1):57-62. PubMed ID: 25514067
[TBL] [Abstract][Full Text] [Related]
35. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.
Cai Q; Patel C; Kim E; Connolly N; Tunceli O; El Khoury AC
Adv Ther; 2019 Apr; 36(4):858-869. PubMed ID: 30848442
[TBL] [Abstract][Full Text] [Related]
36. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
Winter-van Rossum I; Weiser M; Galderisi S; Leucht S; Bitter I; Glenthøj B; Hasan A; Luykx J; Kupchik M; Psota G; Rocca P; Stefanis N; Teitelbaum A; Bar Haim M; Leucht C; Kemmler G; Schurr T; ; Davidson M; Kahn RS; Fleischhacker WW
Lancet Psychiatry; 2023 Mar; 10(3):197-208. PubMed ID: 36716759
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Concurrent Oral and Long-Acting Injectable Antipsychotic Prescribing at the Minneapolis Veterans Affairs Health Care System.
Dimitropoulos E; Drogemuller L; Wong K
J Clin Psychopharmacol; 2017 Oct; 37(5):605-608. PubMed ID: 28816923
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
